Seoul National University Bundang Hospital (SNUBH)
| República da Coreia | Turquia | Áustria | |
| Quimioterapia para cancro da mama | de $19,200 | de $1,200 | de $15,000 |
| Craniotomia | de $16,500 | de $5,650 | de $20,000 |
| Terapia de radiação para o cancro colorretal | - | de $7,000 | de $12,000 |
| Radiocirurgia estereotáxica | - | de $4,500 | de $17,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Meduloblastoma. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Meduloblastoma e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Meduloblastoma.
O Hospital Severance — o maior hospital multidisciplinar da Coreia do Sul. Foi o primeiro no país a receber a prestigiosa acreditação americana pela qualidade do tratamento — JCI.
A especialização do Severance — oncologia, check-up (exame de saúde), cirurgia da coluna, cirurgia cardíaca e oftalmologia.
As conquistas do hospital incluem a primeira cirurgia cardíaca robótica na Coreia e a primeira implantação na Ásia de um disco espinhal artificial na região cervical.
Anualmente, o Hospital Severance recebe para tratamento mais de 1 000 000 de pacientes internados, dos quais 30 000 são estrangeiros.
O Hospital Gangnam Severance é o maior hospital multidisciplinar de Seul, Coreia do Sul.
Especialização — oncologia, neurocirurgia, neurologia, cardiologia e check-up (exame abrangente).
A clínica foi uma das primeiras em Seul a obter a acreditação americana Joint Commission International. Isso confirma a conformidade com os padrões internacionais de segurança no tratamento e o uso de métodos modernos.
Entre as conquistas do centro médico — o primeiro transplante de pulmão na Coreia do Sul.
O Dr. Do Hyun Nam é um neurocirurgião de renome na Coreia do Sul, especializado na remoção de tumores cerebrais e cirurgias endoscópicas no Samsung Medical Center.
South Korea offers high-tier medulloblastoma treatment through JCI-accredited centers and specialized pediatric neuro-oncology teams. Patients access advanced technologies like stereotaxic radiosurgery and endoscopic brain tumor removal. These facilities provide coordinated oncology and radiation services with significant savings compared to US healthcare costs.
Bookimed Expert Insight: Data shows a clear trend where Korea's largest centers, like Seoul National University Hospital, serve over 10,000 patients daily. This massive volume allows surgeons to see rare medulloblastoma subtypes more frequently than typical Western regional hospitals. Choosing these high-volume state facilities often provides access to the country's most established oncology protocols.
Patient Consensus: Families emphasize the value of fast access to specialized teams that bundle surgery, chemotherapy, and radiation. They note that having all specialists in one system makes managing complex pediatric recovery much easier.
Top South Korean hospitals for medulloblastoma include Seoul National University Hospital, Asan Medical Center, and Severance Hospital. These JCI-accredited facilities use multidisciplinary teams and advanced neurosurgery. Centers like SNUH reported the highest statistics for cancer treatment in the country. Treatment protocols combine surgical resection, radiation, and chemotherapy.
Bookimed Expert Insight: Quality signals for medulloblastoma are found in hospital volume and digital integration. Seoul National University Bundang Hospital uses the unique BESTcare digital system. This infrastructure coordinates care across oncology and neurosurgery departments more efficiently. Such integration is vital for the rapid decision-making required in pediatric brain tumor cases.
Patient Consensus: Families note that successful treatment depends on a unified pediatric neuro-oncology team. Patients emphasize choosing centers that manage surgery, pathology, and radiation in one location.
Medulloblastoma treatment in South Korea follows a multimodal approach starting with surgical resection to remove the tumor. Highly specialized centers utilize craniotomy, followed by targeted chemotherapy and stereotactic radiosurgery. JCI-accredited facilities in Seoul integrate advanced diagnostic tools like CT and long-term MRI follow-up to ensure precision.
Bookimed Expert Insight: South Korea leading centers like Seoul National University Hospital operate as digital hospitals with systems like BESTcare. This digitalization allows for seamless coordination between neurosurgeons and oncologists. Specialized pediatric experts like Dr. Do Hyun Nam focus on endoscopic techniques to reduce recovery times. These institutions manage over 1,000,000 patients yearly, ensuring high surgical volume and clinical expertise.
Patient Consensus: Patients note that treatment is a sequential journey typically moving from operation to radiation and chemotherapy. It is important to plan early for physical and speech therapy to address balance or swallowing issues after surgery.
The overall 5-year survival rate for medulloblastoma exceeds 80% with comprehensive treatment. Outcomes depend primarily on molecular subtype and tumor spread. Standard-risk patients often achieve survival rates between 80% and 90%. High-risk or metastatic cases typically see a 60% survival rate.
Bookimed Expert Insight: South Korea offers a high density of JCI-accredited facilities, like Severance Hospital and Korea University Anam Hospital. Seoul National University Hospital reports some of the highest cancer treatment statistics nationally. This concentration of expertise allows for precise molecular staging, which is critical for determining the specific medulloblastoma subtype and tailoring therapy.
Patient Consensus: Patients emphasize that prognosis is highly risk-dependent and appreciate that many cases are potentially curable with aggressive, multidisciplinary care. They note that long-term monitoring is necessary to manage side effects like cognitive changes and endocrine health.
Total treatment for medulloblastoma in South Korea typically lasts between 6 to 12 months. This timeframe includes initial tumor removal followed by several weeks of recovery. Most patients then undergo multiple cycles of radiation and chemotherapy to eliminate remaining cancer cells.
Bookimed Expert Insight: Data from leading Seoul centers like Severance Hospital shows a focus on staged protocols. Initial surgery is just the first step of a year-long journey. Clinics here utilize digital systems like BESTcare to manage these complex, multi-month timelines. This reduces human error during the transition from neurosurgery to long-term oncology cycles.
Patient Consensus: Patients emphasize that treatment is a marathon of different stages rather than one hospital stay. They note that the start of radiation depends entirely on how quickly the surgical site heals.